Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

 

 

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Feb 23, 2018
Last Price 78.90 Change +0.96(+1.232%) open 78.34 Day High 79.68 52-Week High 82.18
Volume 282,956 Previous Close 77.94 Day Low 77.11 52-Week Low 20.39

Press Releases

Load More